Multiple sclerosis

After fingolimod, more drugs in same class are close to approval for MS

A new drug in the class of sphingosine 1-phosphate receptor modulators for MS has been shown to be effective  – and potentially safer than predecessors – in two trials published this week. If it goes on to gain regulatory approval, ozanimod will follow fingolimod (Gilenya) and siponimod (Mayzent) as a treatment of secondary progressive MS, ...

Already a member?

Login to keep reading.

© 2021 the limbic